2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
03/08/19Exicure, Inc. Reports Full Year 2018 Financial Results and Corporate Progress
Completed Phase 1 clinical trials of two drugs and began public trading SKOKIE, Ill.--(BUSINESS WIRE)--Mar. 8, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today reported full year financial results for the year ended December 31, 2018 and provided an update on corporate progress. “We’re very proud of our achievements on each of our stra... 
Printer Friendly Version
02/25/19Exicure Announces Dosing of First Patient in Phase 1b/2 Immuno-oncology Trial
SKOKIE, Ill.--(BUSINESS WIRE)--Feb. 25, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it has dosed the first patient in its multicenter, open-label, Phase 1b/2 study of AST-008 combined with pembrolizumab. Enrollment in the trial is open to patients with superficial injectable tumors in advanced or metastatic solid tumor conditio... 
Printer Friendly Version
02/21/19Exicure to Present at the 12th Annual European Life Sciences CEO Forum
SKOKIE, Ill.--(BUSINESS WIRE)--Feb. 21, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann, will present a corporate update at the 12th Annual European Life Sciences CEO Forum being held February 25-26, 2019 at the Hilton Zurich Airport Hotel in Zurich, Switzerland. The presentation will occur on Monday,... 
Printer Friendly Version
02/19/19Exicure Announces License and Development Agreement with Dermelix Biotherapeutics in Rare Genetic Skin Diseases
– Agreement Leverages Recent Clinical Success of Exicure in Dermatology – SKOKIE, Ill. & NEW YORK--(BUSINESS WIRE)--Feb. 19, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, and Dermelix Biotherapeutics, a biopharmaceutical company focused on the development of innovative treatments for rare genetic skin diseases, today announced... 
Printer Friendly Version
02/18/19Exicure to Present at SMi’s RNA Therapeutics 2019 Conference
SKOKIE, Ill.--(BUSINESS WIRE)--Feb. 18, 2019-- Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann, will present at SMi’s RNA Therapeutics 2019 Conference being held February 20-21, 2019 at the Copthorne Tara Hotel in London, UK. Dr. Giljohann’s presentation titled “Spherical Nucleic Acids: Clinical Progress” will ... 
Printer Friendly Version
02/06/19Exicure to Present at BIO CEO & Investor Conference 2019
SKOKIE, Ill.--(BUSINESS WIRE)--Feb. 6, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann, will present a corporate update on Monday, February 11, 2019 at 11:15 am EST at the BIO CEO & Investor Conference. The presentation will be in the Hudson/Empire room at the New York Marriott Marquis in New York City. ... 
Printer Friendly Version
02/05/19Exicure Announces US Clinical Sites for Phase 1b/2 Oncology Trial
SKOKIE, Ill.--(BUSINESS WIRE)--Feb. 5, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced four of the clinical trial sites for the Company’s Phase 1b/2 trial of AST-008. “Exicure is thrilled to announce the four initial sites for the Phase 1b/2 clinical trial to evaluate our immune system activating spherical nucleic acid ... 
Printer Friendly Version
02/04/19Exicure to Present at the Immuno-Oncology 360° Conference
SKOKIE, Ill.--(BUSINESS WIRE)--Feb. 4, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann, will present at the Immuno-Oncology 360° Conference (IO360°) being held February 6-8, 2019 at the Crowne Plaza Times Square in New York City. Dr. Giljohann’s presentation titled “Innate Immune System Activation wit... 
Printer Friendly Version
01/03/19Exicure to Present at Biotech Showcase 2019 on January 8th at 2:30 pm PT
SKOKIE, Ill.--(BUSINESS WIRE)--Jan. 3, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann, will present a corporate update on Tuesday, January 8, 2019 from 2:30 pm to 3:00 pm PT at the Biotech Showcase 2019. The presentation will be in the Franciscan A room on the Ballroom level of the ... 
Printer Friendly Version

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet